A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Vizimpro
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Sep 2022 Planned number of patients changed from 300 to 1200.
- 01 Feb 2022 Actual study start date changed from 7 Mar 2021 to 12 Mar 2021.
- 27 Jan 2022 Status changed from active, no longer recruiting to recruiting.